The treatment of urothelial carcinoma has developed significantly in recent years. Modern immunotherapies, antibody-drug conjugates (ADCs) and targeted substances complement conventional chemotherapies and increasingly enable individualized treatment strategies. New data from 2025 and 2026 show that combination therapies, maintenance concepts and biomarker-based approaches in particular are gaining in importance. In addition, modern therapy planning is benefiting from more precise diagnostics.
Dieser Inhalt ist nur für Benutzer der Gruppe: Medizinische Fachperson zugänglich
Jetzt beitreten
Jetzt beitreten
Already a member? Log in here
